Cullinan Therapeutics (Cullinan Therapeutics) Beginning Cash Position : $64.85 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Beginning Cash Position?

Cullinan Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $64.85 Mil.

Cullinan Therapeutics's quarterly Beginning Cash Position increased from Jun. 2023 ($122.13 Mil) to Sep. 2023 ($141.83 Mil) but then declined from Sep. 2023 ($141.83 Mil) to Dec. 2023 ($64.85 Mil).

Cullinan Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($168.20 Mil) to Dec. 2022 ($59.77 Mil) but then increased from Dec. 2022 ($59.77 Mil) to Dec. 2023 ($156.15 Mil).

Cullinan Therapeutics Beginning Cash Position Historical Data

The historical data trend for Cullinan Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Beginning Cash Position Chart

Cullinan Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

33.83

63.25

168.20

59.77

156.15

Cullinan Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial														242.66	156.15	122.13	141.83	64.85

Cullinan Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Cullinan Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics (Cullinan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, Suite 520, Cambridge, MA, USA, 02142

Website

https://www.cullinanoncology.com

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Executives

Nadim Ahmed	director, officer: President and CEO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer	officer: Chief Legal Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson	officer: See Remarks	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio	officer: Chief Financial Officer	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan	director	C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2	10 percent owner	74 GRAND RUE, LUXEMBURG N4 L-1660
Savill Corrine	officer: Acting Chief Business Officer	C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
F2 Bioscience I 2017 Ltd	10 percent owner	8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin	director	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104